pubmed-article:12559795 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:12559795 | lifeskim:mentions | umls-concept:C0062527 | lld:lifeskim |
pubmed-article:12559795 | lifeskim:mentions | umls-concept:C1704632 | lld:lifeskim |
pubmed-article:12559795 | lifeskim:mentions | umls-concept:C0871261 | lld:lifeskim |
pubmed-article:12559795 | lifeskim:mentions | umls-concept:C2911692 | lld:lifeskim |
pubmed-article:12559795 | lifeskim:mentions | umls-concept:C1706817 | lld:lifeskim |
pubmed-article:12559795 | lifeskim:mentions | umls-concept:C0681842 | lld:lifeskim |
pubmed-article:12559795 | lifeskim:mentions | umls-concept:C2713304 | lld:lifeskim |
pubmed-article:12559795 | pubmed:issue | 11-12 | lld:pubmed |
pubmed-article:12559795 | pubmed:dateCreated | 2003-1-31 | lld:pubmed |
pubmed-article:12559795 | pubmed:abstractText | Sixty healthy nonresponders were randomized to receive intramuscular (IM) high dose hepatitis B virus (HBV) vaccine versus IM standard dose HBV vaccine plus granulocyte-macrophage colony-stimulating factor (GM-CSF) at 0-2 months. Antibody to hepatitis B surface antigen was measured 1 month after each dose and 3 months after the last dose. Two regimens were equivalent in eliciting seroprotection in nonresponders. Weight-height index (WHI) <39 and alanine transaminase (ALT) <39 mg/dl predicted which nonresponders would seroconvert. A three-dose regimen of standard dose HBV vaccine plus GM-CSF may be a useful for seroprotection of healthy nonresponders. | lld:pubmed |
pubmed-article:12559795 | pubmed:language | eng | lld:pubmed |
pubmed-article:12559795 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12559795 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:12559795 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12559795 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12559795 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12559795 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12559795 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12559795 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12559795 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:12559795 | pubmed:month | Mar | lld:pubmed |
pubmed-article:12559795 | pubmed:issn | 0264-410X | lld:pubmed |
pubmed-article:12559795 | pubmed:author | pubmed-author:BertinoJoseph... | lld:pubmed |
pubmed-article:12559795 | pubmed:author | pubmed-author:NafzigerAnne... | lld:pubmed |
pubmed-article:12559795 | pubmed:author | pubmed-author:DrusanoGeorge... | lld:pubmed |
pubmed-article:12559795 | pubmed:author | pubmed-author:RamseyKeith... | lld:pubmed |
pubmed-article:12559795 | pubmed:author | pubmed-author:KimMyong-JinM... | lld:pubmed |
pubmed-article:12559795 | pubmed:author | pubmed-author:KeyserlingHar... | lld:pubmed |
pubmed-article:12559795 | pubmed:author | pubmed-author:HarroClayton... | lld:pubmed |
pubmed-article:12559795 | pubmed:copyrightInfo | Copyright 2002 Elsevier Science Ltd. | lld:pubmed |
pubmed-article:12559795 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:12559795 | pubmed:day | 7 | lld:pubmed |
pubmed-article:12559795 | pubmed:volume | 21 | lld:pubmed |
pubmed-article:12559795 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:12559795 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:12559795 | pubmed:pagination | 1174-9 | lld:pubmed |
pubmed-article:12559795 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
pubmed-article:12559795 | pubmed:meshHeading | pubmed-meshheading:12559795... | lld:pubmed |
pubmed-article:12559795 | pubmed:meshHeading | pubmed-meshheading:12559795... | lld:pubmed |
pubmed-article:12559795 | pubmed:meshHeading | pubmed-meshheading:12559795... | lld:pubmed |
pubmed-article:12559795 | pubmed:meshHeading | pubmed-meshheading:12559795... | lld:pubmed |
pubmed-article:12559795 | pubmed:meshHeading | pubmed-meshheading:12559795... | lld:pubmed |
pubmed-article:12559795 | pubmed:meshHeading | pubmed-meshheading:12559795... | lld:pubmed |
pubmed-article:12559795 | pubmed:meshHeading | pubmed-meshheading:12559795... | lld:pubmed |
pubmed-article:12559795 | pubmed:meshHeading | pubmed-meshheading:12559795... | lld:pubmed |
pubmed-article:12559795 | pubmed:meshHeading | pubmed-meshheading:12559795... | lld:pubmed |
pubmed-article:12559795 | pubmed:meshHeading | pubmed-meshheading:12559795... | lld:pubmed |
pubmed-article:12559795 | pubmed:meshHeading | pubmed-meshheading:12559795... | lld:pubmed |
pubmed-article:12559795 | pubmed:meshHeading | pubmed-meshheading:12559795... | lld:pubmed |
pubmed-article:12559795 | pubmed:meshHeading | pubmed-meshheading:12559795... | lld:pubmed |
pubmed-article:12559795 | pubmed:meshHeading | pubmed-meshheading:12559795... | lld:pubmed |
pubmed-article:12559795 | pubmed:meshHeading | pubmed-meshheading:12559795... | lld:pubmed |
pubmed-article:12559795 | pubmed:meshHeading | pubmed-meshheading:12559795... | lld:pubmed |
pubmed-article:12559795 | pubmed:year | 2003 | lld:pubmed |
pubmed-article:12559795 | pubmed:articleTitle | Revaccination of healthy nonresponders with hepatitis B vaccine and prediction of seroprotection response. | lld:pubmed |
pubmed-article:12559795 | pubmed:affiliation | Clinical Pharmacology Research Center, Bassett Healthcare, One Atwell Road, Cooperstown, NY 13326-1394, USA. | lld:pubmed |
pubmed-article:12559795 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:12559795 | pubmed:publicationType | Clinical Trial | lld:pubmed |
pubmed-article:12559795 | pubmed:publicationType | Comparative Study | lld:pubmed |
pubmed-article:12559795 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
pubmed-article:12559795 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
pubmed-article:12559795 | pubmed:publicationType | Multicenter Study | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12559795 | lld:pubmed |